Waiting for answer This question has not been answered yet. You can hire a professional tutor to get the answer.
I will pay for the following article Determining HER2 Expression and HER2 Glycosylation Changes. The work is to be 8 pages with three to five sources, with in-text citations and a reference page.
I will pay for the following article Determining HER2 Expression and HER2 Glycosylation Changes. The work is to be 8 pages with three to five sources, with in-text citations and a reference page. In the last years, multiple attempts have been conducted to develop strategies that could actually determine the over-expression of HER 2 positive breast cancer indicators in secondary breast cancer cell lines compared to the primary cell line expression and the glycosylation process changes connected. In this regard, breast cancer lines have significantly been used to investigate cancer pathobiology for new emerging therapies thereby identifying the cancer oncogenesis as a molecularly heterogeneous disease (Schwab & Thomson Gale 2008). HER2 overexpression in metastatic breast cancer and O-glycan changes exhibition has been used in invasive breast cancer in conjunction with the therapy involved for the illness. Therefore, HER-2 issues in metastatic versus primary breast cancer overexpression are associated with the HER-2-positive discovered disorder (Tavani, 2006).
The increased prominence of HER-2 overexpression accompanied by glycosylation changes has increased interest in Breast cancer pathobiology researchers and academic learners to focus mainly on the basic theories and explanations for the origin and therapies for this particular condition. Many authors claim that the HER-2 oncogenes have been found to encode a transmembrane tyrosine kinase receptor that is responsible as the central classifier for the targeted therapy and invasive breast cancer disease (Jo & Zeon, 2015). On a broad analysis, the immunohistochemistry, fluorescence and chromogenic in-situ hybridization and the major marketed slide-based HER-2 methods are presented and contrasted broadly against the fundamental background of the HER-2 testing guideline testing (American Society of Clinical Oncology–College of American Pathologists guidelines).
The over-expression of the HER2 receptor and glycosylation changes associated with breast cancer .cell lines in the primary or secondary expression studies is relevant to the oncogenesis practitioners and other health agencies. .
